An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.
口服生物利用度高的 SARS-CoV-2 主蛋白酶抑制剂表现出更高的亲和力和更低的突变敏感性
期刊:Science Translational Medicine
影响因子:14.6
doi:10.1126/scitranslmed.adi0979
Westberg Michael, Su Yichi, Zou Xinzhi, Huang Pinghan, Rustagi Arjun, Garhyan Jaishree, Patel Puja Bhavesh, Fernandez Daniel, Wu Yan, Hao Chenzhou, Lo Chieh-Wen, Karim Marwah, Ning Lin, Beck Aimee, Saenkham-Huntsinger Panatda, Tat Vivian, Drelich Aleksandra, Peng Bi-Hung, Einav Shirit, Tseng Chien-Te K, Blish Catherine, Lin Michael Z